Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven
precision cardiovascular medicine company, announces a strategic
partnership with Navierre, an innovative digital health technology
platform which revolutionizes how patients access healthcare and
serves as a true health companion for every stage from birth to the
golden years with a robust care navigation, wellness, and chronic
care management offering. This collaboration aims to significantly
expand access to Cardio Diagnostics' industry-leading, AI-enabled
precision cardiovascular diagnostic tests.
Heart disease remains the leading cause of death globally,
underscoring the critical need for accessible and innovative
clinical cardiovascular solutions. Current solutions for assessing
the risk for and diagnosing heart disease such as CT imaging are
not highly scalable due to the need for specialized infrastructure
that is not readily available nationwide, especially in rural
America. In contrast, Cardio Diagnostics’ clinical tests, Epi+Gen
CHD and PrecisionCHD, that only require a blood sample that can be
collected in provider settings, at-home or via mobile phlebotomy,
can be scaled nationwide rapidly with minimal to no infrastructure
barriers. By leveraging the rapidly growing telehealth market,
Cardio Diagnostics in partnership with Navierre is poised to
revolutionize the patient cardiovascular care journey through
earlier detection, accessible specialty care, and personalized
prevention.
Cardio Diagnostics' suite of AI-driven solutions, including the
Epi+Gen CHD and PrecisionCHD tests, leverage cutting-edge
epigenetic and genetic science to provide personalized insights
into a patient's risk for coronary heart disease or coronary heart
disease status. By identifying risk earliery and understanding the drivers of the risk,
these tests provide actionable insights so patients and clinicians
can take proactive steps towards prevention and management,
ultimately improving outcomes and saving lives. Through the
Navierre partnership, these transformative tools will now be
accessible to a broader audience, breaking down barriers to
specialty cardiovascular care.
Starting April 1, 2024, Cardio Diagnostics' precision heart
health tests, including its flagship AI-powered epigenetic-genetic
cardiovascular risk, detection, and management tests, will be
available to thousands of patients and clinicians through
Navierre's platform. Navierre-partnered clinicians across the
United States can seamlessly order these tests for their patients,
and consumers can easily register for a profile on the platform to
fill out a health questionnaire and request the clinical test.
"We are thrilled to partner with Navierre to make our
industry-leading cardiovascular clinical tests more widely
available to patients and clinicians nationwide," said Meesha
Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. "Navierre's
innovative platform aligns with our mission to transform
cardiovascular care through AI-driven precision diagnostics and
personalized prevention strategies."
The COVID-19 pandemic has accelerated the adoption of digital
health solutions, with the CDC reporting that 36% of adults used
telehealth services in 2021. According to McKinsey, up to $250
billion of U.S. healthcare spending could be virtualized. This
represents a significant portion of the healthcare market,
estimated to be around 20% of all Medicare, Medicaid, and
commercial outpatient, office, and home health expenditures; this
partnership positions Cardio Diagnostics at the forefront of this
ongoing shift in healthcare delivery.
"Cardio Diagnostics' groundbreaking testing solutions are an
exciting addition to our curated list of products and services we
offer to our users," said Mustafa Dinani, CEO and Co-Founder of
Navierre. "By combining our innovative platform with their
AI-driven precision diagnostics, we empower patients and clinicians
with the tools they need to identify cardiovascular risk early when
it can be most effectively addressed. Together, we are making
significant strides in the fight against the world's leading cause
of death."
The partnership between Cardio Diagnostics and Navierre
represents a significant milestone in the journey to revolutionize
cardiovascular care by harnessing the power of AI, precision
medicine, and digital health. By making innovative diagnostic tools
more accessible and convenient no matter where patients are
located, cardiovascular specialty care can be scaled.
The partnership also underscores Cardio Diagnostics' commitment
to health equity and access. By leveraging Navierre's digital
health platform, the Company aims to bridge the gap in
cardiovascular care, particularly for underserved communities and
those in remote areas who may face challenges in accessing
traditional healthcare services. This collaboration ensures that
individuals can receive specialty cardiovascular care regardless of
location with the most advanced and personalized diagnostic tools
available. Cardio Diagnostics and Navierre are dedicated to
creating a future where no one is left behind in the fight against
cardiovascular disease.
About Cardio Diagnostics Cardio Diagnostics is an
artificial intelligence-powered precision cardiovascular medicine
company that makes cardiovascular disease prevention, detection,
and management more accessible, personalized, and precise. The
Company was formed to further develop and commercialize clinical
tests by leveraging a proprietary Artificial Intelligence
(AI)-driven Integrated Genetic-Epigenetic Engine ("Core
Technology") for cardiovascular disease to become one of the
leading medical technology companies for improving prevention,
detection, and treatment of cardiovascular disease. For more
information, please visit www.cardiodiagnosticsinc.com.
About Navierre Navierre is a consumer-centric digital
health platform revolutionizing how patients access healthcare and
serves as a true health companion for every stage from birth to the
golden years with a robust care navigation, wellness, and chronic
care management offering. Navierre enables patients to create free
health profiles, enable patients to seamlessly aggregate all their
health information in one place, and connect with a network of
licensed clinicians for virtual consultations, treatment, and
diagnostic test recommendations. Navierre's affordable, transparent
cash-pay marketplace includes access to innovative solutions that
are only sometimes covered by insurance. By combining cutting-edge
technology with a focus on quality and cost-effectiveness, Navierre
empowers consumers to take charge of their health journey. Navierre
was founded in 2022 by a team of veteran healthcare technology
entrepreneurs and is backed by leading digital health investors.
For more information, visit www.navierre.com.
Forward-Looking Statements Certain statements and
information included in this press release constitute
"forward-looking statements" within the meaning of the Private
Securities Litigation Act 1995. When used in this press release,
the words or phrases "will," "will likely result," "expected to,"
"will continue," "anticipated," "estimate," "projected," "intend,"
"goal," or similar expressions are intended to identify
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements are
subject to certain risks, known and unknown, and uncertainties,
many of which are beyond the control of the Company. Such
uncertainties and risks include but are not limited to, our ability
to successfully execute our growth strategy, changes in laws or
regulations, economic conditions, dependence on management,
dilution to stockholders, lack of capital, the effects of rapid
growth upon the Company and the ability of management to
effectively respond to the growth and demand for products and
services of the Company, newly developing technologies, the
Company's ability to compete, regulatory matters, protection of
technology, the effects of competition and the ability of the
Company to obtain future financing. An extensive list of factors
that can affect future results are discussed in the Current Report
on Form 10-K for the period ended December 31, 2023 under the
heading "Risk Factors" in Part I, Item IA thereof, and other
documents filed from time to time with the Securities and Exchange
Commission. Such factors could materially adversely affect the
Company's financial performance and could cause the Company's
actual results for future periods to differ materially from any
opinions or statements expressed within this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240404484262/en/
Investors: Gene Mannheimer Investor Relations
855-226-9991 investors@cardiodiagnosticsinc.com Media &
Public Relations: Khullani Abdullahi 855-226-9991
pr@cardiodiagnosticsinc.com
Cardio Diagnostics (NASDAQ:CDIO)
過去 株価チャート
から 10 2024 まで 11 2024
Cardio Diagnostics (NASDAQ:CDIO)
過去 株価チャート
から 11 2023 まで 11 2024
